Charles R.
- Country
- France
- Department
- Thoracic department
Research Overview
- Phase 1 Study of SHP2 Inhibitor BBP-398 and KRAS-G12C Inhibitor Sotorasib in Advanced Solid Tumors with KRAS-G12C Mutation
- Phase III Randomized Controlled Trial of Pembrolizumab with Platinum-Based Chemotherapy Versus Pembrolizumab Monotherapy in First-Line Treatment of NSCLC with PD-L1 ≥50%
- Non-Inferiority Study of Pembrolizumab Maintenance Therapy at Standard vs. Reduced Dose in Metastatic Non-Squamous Lung Cancer
Data & Insights
Has run more than one trial at 301 of 542 partner sites.
Specializations
Lung Cancer Specialization
Primary focus on non-small cell lung cancer (NSCLC) treatment approaches, particularly in advanced and metastatic stages. Extensive involvement in evaluating novel therapeutic combinations for various NSCLC subtypes, including squamous and non-squamous variants.
- Advanced stage NSCLC interventions
- Metastatic disease management
- Immunotherapy applications
Specialized Cancer Treatments
Expert in targeted therapies and immunotherapeutic approaches, with particular attention to PD-L1 expressing tumors. Significant experience in evaluating combination treatments involving novel therapeutic agents.
- Checkpoint inhibitor therapies
- Mutation-specific treatments
- Combination therapy protocols
Rare Lung Cancer Variants
Specialized research in small cell lung cancer (SCLC) and large-cell neuroendocrine carcinomas. Expertise in developing treatment strategies for extensive-stage disease and evaluating novel therapeutic combinations.
- Neuroendocrine tumor treatments
- SCLC therapeutic approaches
- Advanced disease management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.